Edible and medicinal fungi inhibit enzymes linked to diabetes type-2 therapy
2019
Аутори:
Stojković, DejanIvanov, Marija
Petrović, Jovana
Kostić, Marina
Ćirić, Ana
Glamočlija, Jasmina
Soković, Marina
Остала ауторства
Soković, MarinaТип документа:
Конференцијски прилог (Објављена верзија)
,
© 2019 Institute for Biological Research "Siniša Stanković", University of Belgrade
Метаподаци
Приказ свих података о документуАпстракт:
Diabetes mellitus is a chronic disorder of metabolism followed by abnormal rise in
plasma glucose levels, as a consequence of unequilibrated insulin production and/or
insensitivity to the effect of this hormone in signal transduction of cellular receptors.
One of the effective strategies for diabetes type-2 management is the inhibition of
complex polysaccharide hydrolysis by pancreatic α-amylase and absorption limitation
of glucose by inhibiting intestinal α-glucosidase enzyme.
Agaricus blazei Murrill, Coprinus comatus (O.F.Müll.) Pers., Cordyceps militaris (L.) Fr.,
Inonotus obliquus (Ach. ex Pers.) Pilát, Morchella conica Pers. and Phellinus linteus Berk.
& M.A. Curtis were investigated for their antidiabetic properties. In vitro assays on
α-amylase and α-glucosidase enzyme inhibition were performed with methanolic
extracts of the selected mushrooms. Furthermore, we calculated the necessary daily
intake of mushroom extracts and dry mushroom powders based on the equivalent
doses of therapeutic drug acarbose given to diabetic patients per day.
Our comparative study on enzyme inhibition showed that the most promising
potential is ascribed to I. obliquus extract, while no inhibition of α-amylase was recorded
with M. conica and C. militaris methanolic extract at the tested concentration. The lowest
daily intake of mushroom powder was suggested for I. obliquus with the dose of 3 ×
1.148 g/day, while the highest was predicted for P. linteus 3 × 2.215 g/day.
Although majority of previous studies showed in vivo antidiabetic potential of water
and polysaccharidic mushroom extracts by different experimental approaches, our
study is the first highlighting in vitro antidiabetic potential by inhibition of α-amylase
and α-glucosidase with methanolic extracts; which makes the investigated species
more promising for the diabetes type-2 treatment by another additional and different
mechanism of action.
Кључне речи:
Diabetes mellitus; α-Amylase; α-Glucosidase; Mushroom; Edible and medicinalФинансирање / пројекти:
- Карактеризација и примена метаболита гљива и утврђивање потенцијала нових биофунгицида (RS-MESTD-Basic Research (BR or ON)-173032)
У:
- Soković M, editor. Book of abstracts: The 2nd Balkans-China Mini-symposium on Natural Products and Drug Discovery; 2019 Apr 11-13; Belgrade, Serbia. Belgrade: Institute for Biological Research "Siniša Stanković", University of Belgrade; 2019. p 37.